More Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis.
Pontillo G. et al, (2025), Hum Brain Mapp, 46
Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
Pontillo G. et al, (2024), Neurology, 103
The influence of MOGAD on diagnosis of multiple sclerosis using MRI
Geraldes R. et al, (2024), Nature Reviews Neurology
Study of seasonality of attacks in MOG antibody-associated disease.
Francis A. et al, (2024), Mult Scler Relat Disord, 90
A study of referral bias in NMOSD and MOGAD cohorts.
Leal Rato M. et al, (2024), Mult Scler Relat Disord, 85
Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis.
Cagol A. et al, (2024), JAMA Neurol, 81, 143 - 153
Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT).
Samadzadeh S. et al, (2024), Front Immunol, 15
Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
Chen B. et al, (2023), Ann Neurol, 94, 508 - 517
The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD.
Berhanu D. et al, (2023), Mult Scler, 29, 1250 - 1256
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
Cortese R. et al, (2023), Brain, 146, 2489 - 2501
Hirayama disease associated with neurogenic bladder dysfunction
Younus O. et al, (2023), Acta Neurologica Belgica, 123, 675 - 677
Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease.
Camera V. et al, (2023), Brain Commun, 5
Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios.
Carnero Contentti E. et al, (2022), Mult Scler Relat Disord, 61
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
Messina S. et al, (2022), Mult Scler, 28, 217 - 227
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom.
Satukijchai C. et al, (2022), JAMA Netw Open, 5
Brain and spinal cord lesion distribution criteria distinguish ms from nmosd and mogad in a large multi-ethnic cohort and in different onset phenotypes
Carnero Contentti E. et al, (2022), MULTIPLE SCLEROSIS JOURNAL, 28, NP12 - NP13
Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders.
Camera V. et al, (2022), J Neurol Neurosurg Psychiatry, 93, 101 - 111
Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
Juryńczyk M. et al, (2022), J Neurol, 269, 269 - 279